Vaxcel Polymyxin E Side Effects

Systemic Treatment: The likelihood of adverse events may be related to the age, renal function and condition of the patient. In cystic fibrosis patients neurological events have been reported in up to 27% of patients. These are generally mild and resolve during or shortly after treatment. Neurotoxicity may be associated with overdose, failure to reduce the dose in patients with renal insufficiency and concomitant use of either neuromuscular blocking drugs or other drugs with similar neurological effects. Reducing the dose may alleviate symptoms. Effects may include apnoea, transient sensory disturbances (such as facial paraesthesia and vertigo) and rarely, vasomotor instability, slurred speech, visual disturbances, confusion or psychosis. Adverse effects on renal function have been reported, usually following use of higher than recommended doses in patients with normal renal function, or failure to reduce the dosage in patients with renal impairment or during concomitant use of other nephrotoxic drugs. The effects are usually reversible on discontinuation of therapy. Pseudo-Bartter syndrome has been reported after intravenous administration of colistimethate sodium with unknown frequency (see Precautions). In cystic fibrosis patients treated within the recommended dosage limits, nephrotoxicity appears to be rare (less than 1%). In seriously ill hospitalised non-CF patients, signs of nephrotoxicity have been reported in approximately 20% of patients. Hypersensitivity reactions including skin rash and drug fever have been reported. If these occur treatment should be withdrawn. Local irritation at the site of injection may occur.
Inhalation Treatment: Inhalation may induce coughing or bronchospasm. Sore throat or mouth has been reported and may be due to Candida albicans infection or hypersensitivity. Skin rash may also indicate hypersensitivity, if this occurs treatment should be withdrawn.